SynAct Pharma AB
STO:SYNACT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SynAct Pharma AB
Net Issuance of Debt
SynAct Pharma AB
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SynAct Pharma AB
STO:SYNACT
|
Net Issuance of Debt
-kr576k
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Net Issuance of Debt
-kr6.8m
|
CAGR 3-Years
9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Net Issuance of Debt
-kr6.7m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Net Issuance of Debt
-kr424m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-94%
|
CAGR 10-Years
N/A
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Net Issuance of Debt
-kr5.1B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
BioArctic AB
STO:BIOA B
|
Net Issuance of Debt
kr890k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
SynAct Pharma AB
Glance View
SynAct Pharma AB engages in the development of pharmaceutical drugs for the treatment of inflammatory diseases. The company is headquartered in Lund, Skane. The company went IPO on 2016-07-11. The firm is located in Lund, Sweden. The company develops medicines for acute impairment in inflammatory diseases. The firm's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.
See Also
What is SynAct Pharma AB's Net Issuance of Debt?
Net Issuance of Debt
-576k
SEK
Based on the financial report for Dec 31, 2025, SynAct Pharma AB's Net Issuance of Debt amounts to -576k SEK.
What is SynAct Pharma AB's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
16%
Over the last year, the Net Issuance of Debt growth was 3%. The average annual Net Issuance of Debt growth rates for SynAct Pharma AB have been 16% over the past three years .
